PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease-Reference-Cited by-同舟云学术

PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease

Published:2016-12-24 Issue:1 Volume:6 Page:137-148
ISSN:2193-8229
Container-title:Infectious Diseases and Therapy
language:en
Short-container-title:Infect Dis Ther

Author:

Xiao Alan J.,Caro Luzelena,Popejoy Myra W.,Huntington Jennifer A.,Kullar Ravina

Funder

Merck

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40121-016-0143-9.pdf

Reference30 articles.

1. Zhanel GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: a novel cephalosporin/beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014;74:31–51.

2. Farrell DJ, Sader HS, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents. 2014;43:533–9.

3. Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011–2012). Antimicrob Agents Chemother. 2013;57:6305–10.

4. Zerbaxa (ceftolozane and tazobactam) [prescribing information]. Whitehouse Station: Merck Sharp & Dohme, 2015.

5. Miller B, Hershberger E, Benziger D, Trinh M, Friedland I. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother. 2012;56:3086–91.

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Outcomes of Ceftazidime–Avibactam versus Ceftolozane–Tazobactam in Managing Pseudomonal Infections in Patients Undergoing Renal Replacement Therapy;Antibiotics;2024-07-26

2. Understanding antimicrobial pharmacokinetics in critically ill patients to optimize antimicrobial therapy: A narrative review;Journal of Intensive Medicine;2024-07

3. Application of Monte Carlo simulation to optimise the dosage regimen of meropenem in patients with augmented renal clearance for Pseudomonas aeruginosa infection;Heliyon;2024-06

4. What are the optimal pharmacokinetic/pharmacodynamic targets for β-lactamase inhibitors? A systematic review;Journal of Antimicrobial Chemotherapy;2024-03-09

5. Clinical outcomes of ceftolozane-tazobactam dosing in patients with sepsis undergoing renal replacement therapies;Clinical Nephrology;2023-09-01